Form 4: Phathom Pharmaceuticals CEO Terrie Curran Reports Stock Sale to Cover Tax Obligations

Phathom Pharmaceuticals CEO Terrie Curran sold shares to cover tax obligations and acquired shares through the employee stock purchase plan.

Summary

• Terrie Curran, CEO of Phathom Pharmaceuticals, reported a transaction involving the company's common stock.
• On July 15, 2024, Curran sold 33,848 shares at a price of $11.72 to satisfy tax withholding obligations related to the settlement of restricted stock units.
• Following the transaction, Curran directly owns 377,734 shares of Phathom Pharmaceuticals.
• Curran also indirectly owns 3,840.16 shares through a 401(k) plan.
• Additionally, Curran acquired 798 shares under the Phathom Pharmaceuticals, Inc. employee stock purchase plan in July 2024.

Sentiment

Score: 6

Explanation: Neutral sentiment. The stock sale is for tax purposes, and the CEO's participation in the employee stock purchase plan is a positive sign. However, any insider selling can create uncertainty.

Positives

• The CEO's participation in the employee stock purchase plan indicates confidence in the company's future.

Negatives

• The sale of shares, even for tax obligations, could be perceived negatively by some investors.

Risks

• Executive stock sales can sometimes signal a lack of confidence, although this sale is attributed to tax obligations.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. Investors often monitor these filings to gauge executive sentiment and potential future stock performance.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units, which vest over time and are subject to tax obligations upon settlement.
• Selling shares to cover these tax obligations is a common practice among executives at publicly traded companies.
• Comparing Curran's holdings and transactions to those of executives at similar pharmaceutical companies (e.g., executives at companies like Biohaven, Amneal, or Viatris) could provide additional context.

Stakeholder Impact

• The stock sale could have a minor impact on shareholder sentiment.

Key Dates